Tissue Regenix Group PLC (LON:TRX) said on Friday that chief financial officer Paul Devlin will step down and the medical device company has started the process to appoint a successor.
Steve Couldwell, who was named as chief executive in November, said: "Paul played a significant role throughout the fundraise and acquisition process, we wish him every success in the future."
READ: Tissue Regenix appoints non-executive director Couldwell as new chief executive
In August, Tissue raised £40mln from investors, of which £25mln was used to complete the “transformational” acquisition of CellRight Technologies.
Alongside the announcement of Devlin’s departure, the company said it has issued and allotted 552,337 ordinary shares of 0.5p each following the exercise of options.